Inflammation Linked to Inferior Outcomes in Leukemia
WEDNESDAY, Jan. 18, 2023 -- A unique inflammation signature, in which atypical B cells are identified, is associated with worse outcomes in patients with acute myeloid leukemia (AML), according to a study published online Jan. 11 in Nature... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 18, 2023 Category: Pharmaceuticals Source Type: news

Blood Test 24 Hours After Starting Chemo Predicts AML Survival Blood Test 24 Hours After Starting Chemo Predicts AML Survival
Protein changes in peripheral blood samples in the first 24 hours after starting chemotherapy could predict which patients with acute myeloid leukemia respond.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 18, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Patient - Centered Communication Tool Feasible for Seniors With Acute Myeloid Leukemia
Patients, caregivers scored higher on AML knowledge and perceived greater efficacy in communicating with oncologists (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 22, 2022 Category: Cancer & Oncology Tags: Oncology, Geriatrics, Journal, Source Type: news

Patient-Centered Communication Tool Feasible for Seniors With Acute Myeloid Leukemia
THURSDAY, Dec. 22, 2022 -- Incorporation of an innovative patient-centered communication tool (UR-GOAL tool) is feasible for older adults with newly diagnosed acute myeloid leukemia (AML), according to study published online Dec. 19 in Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 22, 2022 Category: Pharmaceuticals Source Type: news

Mayo Clinic Q & amp;A podcast: Advancing treatments for acute myeloid leukemia
Acute myeloid leukemia (AML), also called acute myelogenous leukemia, is a cancer of the blood and bone marrow, the spongy tissue inside bones where blood cells are made. The disease progresses rapidly, affecting a group of white blood cells called myeloid cells, which normally develop into mature red blood cells, white blood cells and platelets.  "There are acute and chronic leukemias, explains Dr. James Foran, an oncologist at Mayo Clinic. "The chronic ones tend to happen… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 20, 2022 Category: Databases & Libraries Source Type: news

REZLIDHIA (olutasidenib), FDA-Approved for Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia, Available at Biologics by McKesson
CARY, N.C., Dec. 19, 2022 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Rigel Pharmaceuticals as one of two specialty pharmacies in a limited distribution network for REZLIDHIATM (olutasidenib), which is indicated for... (Source: McKesson News)
Source: McKesson News - December 19, 2022 Category: Information Technology Source Type: news

' Astonishing' Results: Skip Salvage Chemo, Go Straight to HSCT'Astonishing' Results: Skip Salvage Chemo, Go Straight to HSCT
Investigators said they were astonished by the results they saw when patients with refractory acute myeloid leukemia went straight to an allogeneic stem cell transplant.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 11, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Worldwide Efforts Needed to Close Regional HSCT Utilization Gap Worldwide Efforts Needed to Close Regional HSCT Utilization Gap
Although hematopoietic stem cell transplants (HSCT) offer a cure for acute myeloid leukemia, in some countries only 5% of patients are offered this option.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 10, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA Approves Olutasidenib (Rezlidhia) for Certain Patients With AML FDA Approves Olutasidenib (Rezlidhia) for Certain Patients With AML
The drug has been approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 2, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Rezlidhia (olutasidenib) for Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
December 1, 2022 -- On December 1, 2022, the Food and Drug Administration (FDA) approved olutasidenib (Rezlidhia) capsules for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 1, 2022 Category: Drugs & Pharmacology Source Type: news

“ Why Aren ’ t We All Bacteria? ” Siddhartha Mukherjee Explores the Power of Cells
It’s hard to miss what appears to be dry cleaning hanging on the wall of Siddhartha Mukherjee’s apartment in New York City’s Chelsea neighborhood. The apartment is a sunny, stylish, open space, filled with modern furniture, decorated with sculpture and paintings—and then, in perhaps the most conspicuous spot on the living room, is a brown felt suit with very long pants, draped over a plain wooden hanger. It looks entirely out of place—but it’s not. The suit is the handiwork of German artist Joseph Bueys, who created the improbable bit of fabric art as a tribute to the nomadic Tatars who,...
Source: TIME: Science - October 31, 2022 Category: Science Authors: Jeffrey Kluger Tags: Uncategorized Magazine Science Source Type: news

‘ Why Aren ’ t We All Bacteria? ’ Siddhartha Mukherjee Explores the Power of Cells
It’s hard to miss what appears to be dry cleaning hanging on the wall of Siddhartha Mukherjee’s apartment in New York City’s Chelsea neighborhood. The apartment is a sunny, stylish, open space, filled with modern furniture, decorated with sculpture and paintings—and then, in perhaps the most conspicuous spot on the living room, is a brown felt suit with very long pants, draped over a plain wooden hanger. It looks entirely out of place—but it’s not. The suit is the handiwork of German artist Joseph Bueys, who created the improbable bit of fabric art as a tribute to the nomadic Tatars who,...
Source: TIME: Science - October 31, 2022 Category: Science Authors: Jeffrey Kluger Tags: Uncategorized Magazine Science Source Type: news

Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
Iomab-B met the primary endpoint of durable complete remission of 6-months following initial complete remission after HCT with a p-value of ... Biopharmaceuticals, Oncology Actinium Pharmaceuticals, Iomab-B, targeted radiotherapies, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 31, 2022 Category: Pharmaceuticals Source Type: news

Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment
This final guidance is intended to assist sponsors in the clinical development of drugs and biological products for the treatment of AML. This guidance addresses FDA ’s current thinking regarding the overall development program and clinical trial designs for AML drugs. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 17, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Episode 6: MRD and Relapse in Patients With AML Episode 6: MRD and Relapse in Patients With AML
Drs Gail Roboz and Roland Walter discuss measurable residual disease and relapse in patients with acute myeloid leukemia.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 17, 2022 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news